MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%
Sector Heatmap
Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%
PTGX — Protagonist Therapeutics, Inc
NasdaqProtagonist Therapeutics, Inc
$140.92
+2.23(+1.61%)
- O
- 137.34
- H
- 144.10
- L
- 137.25
- V
- 927.26K
⏱️ End-of-day dataAs of Oct 7, 2026
Chart
About PTGX
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateAug 11, 2016
Employees141
Stock ExchangeNasdaq
Ticker SymbolPTGX
Key Financial Statistics
| Market Cap | $9.06B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $64.50 - $160.81 |
| 52-Week Avg Volume | 817.1K |
| VWAP | $141.82 |
| Transactions | 16,548 |
| Total Recorded Bars | 2,553 days |